دورية أكاديمية
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
| العنوان: | World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. |
|---|---|
| المؤلفون: | Berger TR; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Wen PY; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts., Lang-Orsini M; Division of Neuropathology, Department of Pathology, Massachusetts General Hospital, Boston., Chukwueke UN; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts. |
| المصدر: | JAMA oncology [JAMA Oncol] 2022 Oct 01; Vol. 8 (10), pp. 1493-1501. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago, Il : American Medical Association, [2015]- |
| مواضيع طبية MeSH: | Glioblastoma* , Glioma*/genetics , Glioma*/therapy , Oligodendroglioma*/genetics , Brain Neoplasms*/genetics , Brain Neoplasms*/therapy , Astrocytoma*/genetics , Central Nervous System Neoplasms*/therapy, Humans ; Adult ; Child ; Isocitrate Dehydrogenase/genetics ; World Health Organization ; Mutation |
| مستخلص: | Importance: Previous histologic classifications of brain tumors have been limited by discrepancies in diagnoses reported by neuropathologists and variability in outcomes and response to therapies. Such diagnostic discrepancies have impaired clinicians' ability to select the most appropriate therapies for patients and have allowed heterogeneous populations of patients to be enrolled in clinical trials, hindering the development of more effective therapies. In adult-type diffuse gliomas, histologic classification has a particularly important effect on clinical care. Observations: In 2021, the World Health Organization published the fifth edition of the Classification of Tumors of the Central Nervous System. This classification incorporates advances in understanding the molecular pathogenesis of brain tumors with histopathology in order to group tumors into more biologically and molecularly defined entities. As such, tumor classification is significantly improved through better characterized natural histories. These changes have particularly important implications for gliomas. For the first time, adult- and pediatric-type gliomas are classified separately on the basis of differences in molecular pathogenesis and prognosis. Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocitrate dehydrogenase (IDH) mutant; oligodendroglioma, IDH mutant and 1p/19q codeleted; and glioblastoma, IDH wild type. These major changes are driven by IDH mutation status and include the restriction of the diagnosis of glioblastoma to tumors that are IDH wild type; the reclassification of tumors previously diagnosed as IDH-mutated glioblastomas as astrocytomas IDH mutated, grade 4; and the requirement for the presence of IDH mutations to classify tumors as astrocytomas or oligodendrogliomas. Conclusions and Relevance: The 2021 World Health Organization central nervous system tumor classification is a major advance toward improving the diagnosis of brain tumors. It will provide clinicians with more accurate guidance on prognosis and optimal therapy for patients and ensure that more homogenous patient populations are enrolled in clinical trials, potentially facilitating the development of more effective therapies. |
| المشرفين على المادة: | EC 1.1.1.41 (Isocitrate Dehydrogenase) |
| تواريخ الأحداث: | Date Created: 20220825 Date Completed: 20221024 Latest Revision: 20240614 |
| رمز التحديث: | 20240614 |
| DOI: | 10.1001/jamaoncol.2022.2844 |
| PMID: | 36006639 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!